Partnership expands access to Gauss’s proprietary, EUA-pending COVID-19 rapid antigen test that can be self-administered at-home with results processed on a smartphone within minutes. Ro will complement the cash-pay test with support of healthcare practitioners through its telehealth platform.

Read more here.